Sysmex (OTCMKTS:SSMXY) Releases Earnings Results, Beats Expectations By $0.02 EPS

Sysmex (OTCMKTS:SSMXY) issued its earnings results on Friday. The company reported $0.09 EPS for the quarter, beating analysts’ consensus estimates of $0.07 by $0.02, Zacks reports. Sysmex had a return on equity of 7.23% and a net margin of 7.13%.The firm had revenue of $825.85 million for the quarter, compared to analyst estimates of $739.25 million. Sysmex updated its FY 2026 guidance to 0.382-0.382 EPS.

Sysmex Price Performance

OTCMKTS:SSMXY opened at $10.94 on Friday. Sysmex has a one year low of $8.01 and a one year high of $14.20. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.46 and a current ratio of 3.26. The firm has a market cap of $6.89 billion, a price-to-earnings ratio of 26.05 and a beta of 1.05. The firm’s fifty day moving average is $9.38 and its two-hundred day moving average is $9.08.

Wall Street Analysts Forecast Growth

Separately, Zacks Research lowered shares of Sysmex from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold”.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan?based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high?speed, high?volume testing for blood cell counts and differential analysis.